On September 14, 2026 Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, reported that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux’s novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation. Over time, Janux intends to evaluate JANX013 in combination with additional candidates within its prostate cancer portfolio.
Prostate cancer is the most commonly diagnosed cancer in men, excluding skin cancers. Clinical experience with Janux’s PSMA-targeted T cell engager candidates has demonstrated the potential of tumor-activated T cell immunotherapy in patients with metastatic castration-resistant prostate cancer. CD28 is a key co-stimulatory receptor involved in T-cell activation, expansion, and persistence. JANX013 is designed to selectively deliver CD28 co-stimulation within the tumor microenvironment using Janux’s proprietary tumor-activation technology, with the goal of further enhancing the durability of anti-tumor immune responses while minimizing systemic CD28 activation.
"Co-stimulation plays a critical role in promoting sustained T-cell function and persistence," said Simon Butikofer, M.D., Vice President, Clinical Development. "JANX013 is designed to selectively deliver tumor-restricted co-stimulation in combination with our CD3 T cell engagers, with the goal of extending the durability of anti-tumor immune responses."
"The initiation of the JANX013 clinical program represents an important milestone in the continued evolution of our prostate cancer franchise," said David Campbell, Ph.D., President and Chief Executive Officer of Janux Therapeutics. "By combining complementary tumor-activated immunotherapies, we believe we have an opportunity to further improve long-term outcomes for patients with prostate cancer."
The Phase 1 clinical trial (NCT07813637) is a first-in-human, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX013 in combination with JANX007 in adult patients with mCRPC. In addition to evaluating safety, the study is intended to evaluate biomarkers of immune activation, including T-cell expansion and persistence, to characterize the effects of tumor-restricted CD28 co-stimulation and inform future clinical development of JANX013.
For additional information about the study, please visit ClinicalTrials.gov using the identifier NCT07813637.
(Press release, Janux Therapeutics, SEP 14, 2026, View Source [SID1234670828])